Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Teva Pharmaceutical...

    Teva Pharmaceutical migraine drug clears late-stage study

    Written by Ruby Khatun Khatun Published On 2017-06-02T09:21:10+05:30  |  Updated On 2 Jun 2017 9:21 AM IST
    Teva Pharmaceutical migraine drug clears late-stage study
    Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine cleared a late-stage study, paving the way for a U.S. regulatory submission later this year.

    Patients treated with Teva's drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days for both monthly and quarterly dosing regimens, the Israel-based company said.


    About 40 million Americans suffer from migraine - intense headache characterized by throbbing pain and sensitivity to light and nausea. The condition, which can last for days, is incurable.


    Teva joins companies such as Amgen Inc, Eli Lilly Co and Alder BioPharmaceuticals Inc that are developing similar drugs to target calcitonin gene-related peptide, or CGRP, a protein involved in pain-signaling during migraine.


    The most important data point is that the quarterly dosing regimen worked for Teva, Evercore ISI's Umer Raffat said, noting that Lilly and Amgen's compounds are being developed for use only on a monthly basis.


    In the 1,130-patient trial, fremanezumab was evaluated against a placebo in patients suffering from chronic migraine - those who experience 15 or more headache days per month.


    Data from a separate study in patients with episodic migraine - those who experience up to 14 headache days per month - is expected in the coming weeks.


    Currently, patients are treated with triptans, a class of drugs that hit the market in the 1990s. These medicines work by constricting blood vessels in the brain and cannot be used in up to 35 percent of patients due to high cardiovascular risk.


    A host of other drugs - including anti-depressants, medicines for hypertension and even botox - are also used to treat migraine but with little success.


    Overall, migraine cost the United States roughly $36 billion a year in terms of healthcare and lost productivity, according to the Migraine Research Foundation.


    The lack of effective medicines and the sheer number of patients guarantee that each company's drug, if approved, will eventually generate at least $1 billion in sales, analysts have forecast.


    Teva's U.S.-listed shares were up about 1 percent at $28.11 in early trading on Wednesday.


    (Reporting by Natalie Grover in Bengaluru; Editing by Arun Koyyur)

    antidepressantsBotoxfremanezumabheadacheshypertensionMigrainenauseaTevaTeva PharmaceuticalTeva Pharmaceutical Industries Ltd
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok